The dexamethasone suppression test (DST) in predicting response to desipramine and amitriptyline in depressed outpatients.
The predictive value of the dexamethasone suppression test (DST) was evaluated in two consecutive clinical trials involving 99 individuals treated with amitriptyline or desipramine. Following one week observation, and following one week on low-dose desipramine or amitriptyline (50 mg), all patients who remained depressed (Hamilton score 16 or greater) were given a full clinical trial of either desipramine or amitriptyline (150-300 mg/day) over a minimum 3-5 week period. In all, 68 patients required this trial, 31 receiving amitriptyline and 37 receiving desipramine. For these patients there was no relationship between DST suppression/non-suppression vs clinical response to either desipramine or amitriptyline. There was a non-significant trend for suppressors (negative DST) to respond either spontaneously or to low-dose desipramine or amitriptyline as opposed to non-suppressors (positive DST).
D000639:Amitriptyline / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D003891:Desipramine / Q000627:therapeutic use*; D003907:Dexamethasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D011237:Predictive Value of Tests
D000639:Amitriptyline; D003907:Dexamethasone; D003891:Desipramine; D006854:Hydrocortisone